Literature DB >> 20579805

Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments.

Jian-Zhen Xu1, Chi-Wai Wong.   

Abstract

Gene microarray is a powerful platform to investigate the expression patterns of thousands of genes simultaneously. One central objective of such analysis is to select sets of genes (i.e., gene signatures) which correlate with clinical characteristics, such as disease subtype diagnosis, response to drug treatment and prognosis. However, previous studies have found that mRNA signatures are highly unstable and strongly depend on the selection of patient samples. Based on five large microRNA profiling datasets, we empirically found that microRNA signatures are also generally unstable. Therefore, concerns arise regarding the reproducibility and clinical applicability of these derived gene signatures. Here, we first provide a brief review on the sources of variability and different interpretations of multiple distinct gene signatures. We then focus on those recent methodological progresses aimed at developing more stable gene signatures. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579805     DOI: 10.1016/j.canlet.2010.05.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  MicroRNA expression profiling in human Barrett's carcinogenesis.

Authors:  Matteo Fassan; Stefano Volinia; Jeff Palatini; Marco Pizzi; Raffaele Baffa; Marina De Bernard; Giorgio Battaglia; Paola Parente; Carlo M Croce; Giovanni Zaninotto; Ermanno Ancona; Massimo Rugge
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

Review 2.  Cancer microRNAs: from subtype profiling to predictors of response to therapy.

Authors:  Elcie Chan; Daniel Estévez Prado; Joanne Barnes Weidhaas
Journal:  Trends Mol Med       Date:  2011-02-25       Impact factor: 11.951

3.  Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data.

Authors:  K Y Yeung; T A Gooley; A Zhang; A E Raftery; J P Radich; V G Oehler
Journal:  Bioinformatics       Date:  2012-01-31       Impact factor: 6.937

Review 4.  MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Authors:  Ji Qi; David Mu
Journal:  Front Med       Date:  2012-04-18       Impact factor: 4.592

Review 5.  Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.

Authors:  Lorenzo F Sempere
Journal:  Expert Rev Mol Diagn       Date:  2011-11       Impact factor: 5.225

6.  Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.

Authors:  Alexander R Gupta; Gavitt A Woodard; David M Jablons; Michael J Mann; Johannes R Kratz
Journal:  Future Oncol       Date:  2021-08-26       Impact factor: 3.674

7.  Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Authors:  Carmen D Herling; Kevin R Coombes; Axel Benner; Johannes Bloehdorn; Lynn L Barron; Zachary B Abrams; Tadeusz Majewski; Jolanta E Bondaruk; Jasmin Bahlo; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer; Bogdan A Czerniak; Christopher C Oakes; Alessandra Ferrajoli; Michael J Keating; Lynne V Abruzzo
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

8.  Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies.

Authors:  Rotem Ben-Hamo; Sol Efroni
Journal:  BMC Syst Biol       Date:  2012-01-11

9.  Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression.

Authors:  Rotem Ben-Hamo; Sol Efroni
Journal:  Genome Med       Date:  2011-11-28       Impact factor: 11.117

Review 10.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  EMBO Mol Med       Date:  2012-02-20       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.